SG11201901991QA - Methods of detecting per cell pd-l1 expression and uses thereof - Google Patents
Methods of detecting per cell pd-l1 expression and uses thereofInfo
- Publication number
- SG11201901991QA SG11201901991QA SG11201901991QA SG11201901991QA SG11201901991QA SG 11201901991Q A SG11201901991Q A SG 11201901991QA SG 11201901991Q A SG11201901991Q A SG 11201901991QA SG 11201901991Q A SG11201901991Q A SG 11201901991QA SG 11201901991Q A SG11201901991Q A SG 11201901991QA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- methods
- expression
- california
- per cell
- Prior art date
Links
- 102000008096 B7-H1 Antigen Human genes 0.000 abstract 4
- 108010074708 B7-H1 Antigen Proteins 0.000 abstract 4
- 210000004027 cell Anatomy 0.000 abstract 4
- 240000005020 Acaciella glauca Species 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 230000009826 neoplastic cell growth Effects 0.000 abstract 2
- 235000003499 redwood Nutrition 0.000 abstract 2
- 239000006285 cell suspension Substances 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 210000005170 neoplastic cell Anatomy 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/30—Staining; Impregnating ; Fixation; Dehydration; Multistep processes for preparing samples of tissue, cell or nucleic acid material and the like for analysis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume, or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Electro-optical investigation, e.g. flow cytometers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume, or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Electro-optical investigation, e.g. flow cytometers
- G01N15/1456—Electro-optical investigation, e.g. flow cytometers without spatial resolution of the texture or inner structure of the particle, e.g. processing of pulse signals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume, or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N2015/1006—Investigating individual particles for cytology
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume, or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Electro-optical investigation, e.g. flow cytometers
- G01N2015/1486—Counting the particles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70532—B7 molecules, e.g. CD80, CD86
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662384037P | 2016-09-06 | 2016-09-06 | |
PCT/US2017/050322 WO2018048936A1 (en) | 2016-09-06 | 2017-09-06 | Methods of detecting per cell pd-l1 expression and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201901991QA true SG11201901991QA (en) | 2019-04-29 |
Family
ID=61561676
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201901991QA SG11201901991QA (en) | 2016-09-06 | 2017-09-06 | Methods of detecting per cell pd-l1 expression and uses thereof |
Country Status (11)
Country | Link |
---|---|
US (1) | US10782298B2 (ja) |
EP (1) | EP3510378A4 (ja) |
JP (2) | JP2019535001A (ja) |
CN (2) | CN109906367A (ja) |
BR (1) | BR112019004470A2 (ja) |
CA (1) | CA3036278A1 (ja) |
CR (1) | CR20190172A (ja) |
IL (1) | IL265175A (ja) |
MX (1) | MX2019002578A (ja) |
SG (1) | SG11201901991QA (ja) |
WO (2) | WO2018048936A1 (ja) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109906367A (zh) * | 2016-09-06 | 2019-06-18 | 茵赛德斯有限公司 | 检测每个细胞的pd-l1表达的方法及其用途 |
US11726089B2 (en) | 2016-09-06 | 2023-08-15 | Incelldx, Inc. | Methods of assaying neoplastic and neoplasia-related cells and uses thereof |
EP3853610A1 (en) * | 2018-09-20 | 2021-07-28 | Ventana Medical Systems, Inc. | Size-based gating to analyze flow cytometry data |
US20210405057A1 (en) * | 2018-11-09 | 2021-12-30 | Pierian Biosciences, LLC | Methods and compositions for determining the composition of a tumor microenvironment |
EP3924521A4 (en) * | 2019-02-15 | 2023-03-29 | IncellDx, Inc. | BLADDER-ASSOCIATED SPECIMEN ASSAY, IDENTIFICATION AND TREATMENT OF BLADDER-ASSOCIATED NEOPLASIA, AND KITS FOR USE THEREOF |
CN110142068B (zh) * | 2019-06-12 | 2024-02-02 | 杭州华得森生物技术有限公司 | 一种上皮间质混合型循环肿瘤细胞检测试剂盒及方法 |
CN111735955A (zh) * | 2020-04-20 | 2020-10-02 | 山东省肿瘤防治研究院(山东省肿瘤医院) | 一种肝细胞癌患者外周血循环肿瘤细胞上pd-l1表达的免疫荧光检测方法 |
IL305795A (en) * | 2021-03-10 | 2023-11-01 | B G Negev Technologies & Applications Ltd At Ben Gurion Univ | Reporter cells expressing chimeric proteins for use in determining the presence and or activity of immune barrier molecules |
CN113358872B (zh) * | 2021-06-03 | 2022-10-21 | 中山大学肿瘤防治中心(中山大学附属肿瘤医院、中山大学肿瘤研究所) | 用于评估肿瘤免疫治疗疗效的标志物组及系统 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7226748B2 (en) * | 2003-01-03 | 2007-06-05 | Aurelium Biopharma, Inc. | HSC70 directed diagnostics and therapeutics for multidrug resistant neoplastic disease |
JP5303146B2 (ja) * | 2004-10-06 | 2013-10-02 | メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ | B7−h1ならびに癌の診断、予後診断および処置の方法 |
JPWO2007136026A1 (ja) * | 2006-05-19 | 2009-10-01 | 忠和 鄭 | 抗原タンパク質の定量方法及び定量用キット |
US9856320B2 (en) * | 2012-05-15 | 2018-01-02 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
AR095363A1 (es) | 2013-03-15 | 2015-10-14 | Genentech Inc | Biomarcadores y métodos para el tratamiento de condiciones relacionadas con pd-1 y pd-l1 |
KR102276644B1 (ko) * | 2013-09-04 | 2021-07-13 | 브리스톨-마이어스 스큅 컴퍼니 | 면역조절제로서 유용한 화합물 |
AU2013400609B9 (en) | 2013-09-13 | 2020-03-05 | Beigene Switzerland Gmbh | Anti-PD1 antibodies and their use as therapeutics and diagnostics |
WO2015061796A1 (en) * | 2013-10-25 | 2015-04-30 | Nodality Inc. | Methods and compositions for immunomodulation |
JP6355154B2 (ja) * | 2014-04-03 | 2018-07-11 | 公益財団法人ヒューマンサイエンス振興財団 | 診断補助方法 |
CU20170052A7 (es) * | 2014-10-14 | 2017-11-07 | Dana Farber Cancer Inst Inc | Moléculas de anticuerpo que se unen a pd-l1 |
EP3207377A4 (en) | 2014-10-15 | 2018-05-02 | Epic Sciences, Inc. | Circulating tumor cell diagnostics for therapy targeting pd-l1 |
CN108026533B (zh) * | 2015-09-01 | 2021-08-17 | 中央研究院 | 拮抗性pdl1适体及其在癌症治疗中的应用 |
US20190085401A1 (en) | 2015-10-27 | 2019-03-21 | Pharmassist Ltd | Method for the quantification of pd-l1 expression |
CN109906367A (zh) | 2016-09-06 | 2019-06-18 | 茵赛德斯有限公司 | 检测每个细胞的pd-l1表达的方法及其用途 |
-
2017
- 2017-09-06 CN CN201780063086.4A patent/CN109906367A/zh active Pending
- 2017-09-06 JP JP2019512878A patent/JP2019535001A/ja not_active Ceased
- 2017-09-06 EP EP17849473.8A patent/EP3510378A4/en active Pending
- 2017-09-06 SG SG11201901991QA patent/SG11201901991QA/en unknown
- 2017-09-06 BR BR112019004470A patent/BR112019004470A2/pt not_active Application Discontinuation
- 2017-09-06 CR CR20190172A patent/CR20190172A/es unknown
- 2017-09-06 WO PCT/US2017/050322 patent/WO2018048936A1/en unknown
- 2017-09-06 MX MX2019002578A patent/MX2019002578A/es unknown
- 2017-09-06 CA CA3036278A patent/CA3036278A1/en not_active Abandoned
-
2018
- 2018-01-03 US US15/861,352 patent/US10782298B2/en active Active
-
2019
- 2019-01-02 CN CN201980016405.5A patent/CN112088309A/zh active Pending
- 2019-01-02 WO PCT/US2019/012074 patent/WO2019136082A1/en active Application Filing
- 2019-03-05 IL IL265175A patent/IL265175A/en unknown
-
2022
- 2022-06-14 JP JP2022096028A patent/JP2022133307A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
IL265175A (en) | 2019-05-30 |
JP2019535001A (ja) | 2019-12-05 |
MX2019002578A (es) | 2019-09-18 |
US20180136214A1 (en) | 2018-05-17 |
CR20190172A (es) | 2019-06-13 |
US10782298B2 (en) | 2020-09-22 |
CA3036278A1 (en) | 2018-03-15 |
EP3510378A1 (en) | 2019-07-17 |
CN109906367A (zh) | 2019-06-18 |
JP2022133307A (ja) | 2022-09-13 |
BR112019004470A2 (pt) | 2019-09-03 |
WO2018048936A1 (en) | 2018-03-15 |
CN112088309A (zh) | 2020-12-15 |
EP3510378A4 (en) | 2020-07-08 |
WO2019136082A1 (en) | 2019-07-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201901991QA (en) | Methods of detecting per cell pd-l1 expression and uses thereof | |
SG11201908719QA (en) | Biomarkers and car t cell therapies with enhanced efficacy | |
SG11201907566TA (en) | Methods and compositions for labeling cells | |
SG11201811740WA (en) | Systems and methods for identifying risky driving behavior | |
SG11201810221YA (en) | Fidelity estimation for quantum computing systems | |
SG11201910019PA (en) | Microorganisms and methods for producing cannabinoids and cannabinoid derivatives | |
SG11201808196UA (en) | Neoantigens and methods of their use | |
SG11201908787WA (en) | Novel bispecific antigen binding molecules capable of specific binding to cd40 and to fap | |
SG11201803983UA (en) | Transformable tagging compositions, methods, and processes incorporating same | |
SG11201909652WA (en) | Neoantigen identification, manufacture, and use | |
SG11201810611YA (en) | Coumarin compounds and their uses as fluorescent labels | |
SG11201810633WA (en) | New fluorescent dyes and their uses as biomarkers | |
SG11201901577SA (en) | Method and system for fast tracking navigation of blockchains via data manipulation | |
SG11201808022WA (en) | Selection and cloning of t lymphocytes in a microfluidic device | |
SG11201900772YA (en) | Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors | |
SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
SG11201810887UA (en) | Baff-r targeted chimeric antigen receptor-modified t-cells and uses thereof | |
SG11201907383QA (en) | Systems and methods for vehicle sharing service | |
SG11201804360XA (en) | Mat2a inhibitors for treating mtap null cancer | |
SG11201804144UA (en) | High-throughput imaging-based methods for predicting cell-type-specific toxicity of xenobiotics with diverse chemical structures | |
SG11201908127WA (en) | Method for producing multispecific antibodies | |
SG11201811329UA (en) | Spheroids including biologically-relevant materials and related methods | |
SG11201806284TA (en) | Low pressure separator having an internal divider and uses therefor | |
SG11201811550XA (en) | Demand prediction for time-expiring inventory | |
SG11201907764PA (en) | Methods for screening infections |